临床合理用药杂志
臨床閤理用藥雜誌
림상합리용약잡지
CHINESE JOURNAL OF CLINICAL RATIONAL DRUG USE
2014年
32期
1-2
,共2页
充血性心力衰竭%厄贝沙坦氢氯噻嗪片%倍他乐克%左室重构
充血性心力衰竭%阨貝沙坦氫氯噻嗪片%倍他樂剋%左室重構
충혈성심력쇠갈%액패사탄경록새진편%배타악극%좌실중구
Chronrc heart failiure%Irbesartan and hydrochlorothiazide tablets%Metoprolol%Left ventricular remodeling
目的：探讨慢性心力衰竭（CHF）患者应用厄贝沙坦氢氯噻嗪片（依伦平）和（或）倍他乐克对改善心室重构的作用。方法选取 CHF 患者90例，随机分为 A、B 和 C 组各30例。A 组给予依伦平（厄贝沙坦150mg +氢氯噻嗪12.5mg）1片/ d；B 组给予倍他乐克50~100mg/ d；C 组给予依伦平（厄贝沙坦150mg +氢氯噻嗪12.5mg）1片/d +倍他乐克50~100mg/ d。均服药8周。治疗前后分别测定超声心动图指标[左室收缩末期容积（LVESV）、左室舒张末期容积（LVEDV）和左室射血分数（LVEF）]。结果3组 CHF 患者治疗后超声心动图指标比较，差别均有统计学意义（P <0.01）；3组患者治疗后 LVESV、LVEDV 均较治疗前减少，LVEF 较治疗前均升高，差异有统计学意义（P <0.05）；C 组患者治疗后 LVEVS、LVEDV 低于 A、B 组，LVEF 高于 A、B 组，差异有统计学意义（P <0.05），A、B 组超声心动图指标比较，差异均无统计学意义（P >0.05）。结论依伦平联合倍他乐克治疗 CHF 效果明显优化于单用依伦平或倍他乐克治疗，能更有效地改善心室重构。
目的：探討慢性心力衰竭（CHF）患者應用阨貝沙坦氫氯噻嗪片（依倫平）和（或）倍他樂剋對改善心室重構的作用。方法選取 CHF 患者90例，隨機分為 A、B 和 C 組各30例。A 組給予依倫平（阨貝沙坦150mg +氫氯噻嗪12.5mg）1片/ d；B 組給予倍他樂剋50~100mg/ d；C 組給予依倫平（阨貝沙坦150mg +氫氯噻嗪12.5mg）1片/d +倍他樂剋50~100mg/ d。均服藥8週。治療前後分彆測定超聲心動圖指標[左室收縮末期容積（LVESV）、左室舒張末期容積（LVEDV）和左室射血分數（LVEF）]。結果3組 CHF 患者治療後超聲心動圖指標比較，差彆均有統計學意義（P <0.01）；3組患者治療後 LVESV、LVEDV 均較治療前減少，LVEF 較治療前均升高，差異有統計學意義（P <0.05）；C 組患者治療後 LVEVS、LVEDV 低于 A、B 組，LVEF 高于 A、B 組，差異有統計學意義（P <0.05），A、B 組超聲心動圖指標比較，差異均無統計學意義（P >0.05）。結論依倫平聯閤倍他樂剋治療 CHF 效果明顯優化于單用依倫平或倍他樂剋治療，能更有效地改善心室重構。
목적：탐토만성심력쇠갈（CHF）환자응용액패사탄경록새진편（의륜평）화（혹）배타악극대개선심실중구적작용。방법선취 CHF 환자90례，수궤분위 A、B 화 C 조각30례。A 조급여의륜평（액패사탄150mg +경록새진12.5mg）1편/ d；B 조급여배타악극50~100mg/ d；C 조급여의륜평（액패사탄150mg +경록새진12.5mg）1편/d +배타악극50~100mg/ d。균복약8주。치료전후분별측정초성심동도지표[좌실수축말기용적（LVESV）、좌실서장말기용적（LVEDV）화좌실사혈분수（LVEF）]。결과3조 CHF 환자치료후초성심동도지표비교，차별균유통계학의의（P <0.01）；3조환자치료후 LVESV、LVEDV 균교치료전감소，LVEF 교치료전균승고，차이유통계학의의（P <0.05）；C 조환자치료후 LVEVS、LVEDV 저우 A、B 조，LVEF 고우 A、B 조，차이유통계학의의（P <0.05），A、B 조초성심동도지표비교，차이균무통계학의의（P >0.05）。결론의륜평연합배타악극치료 CHF 효과명현우화우단용의륜평혹배타악극치료，능경유효지개선심실중구。
Objective To evaluate the effects of irbesartan and hydrochlorothiazide tablets and(or)metoprolol on the improvement of myocardial remodeling in patients with chronic heart failure(CHF). Methods Totally 90 CHF patients were equally randomized into A,B and C group,each of 30 cases. A group:irbesartan and hydrochlorothiazide tablets group(1 piece/ d of Irbesartan and Hydrochlorothiazide tablets for 8 weeks). B group:metoprolol group(50 ~ 100mg/ d of metoprolol for 8 weeks). C group:combined group(1piece/ d of irbesartan and hydrochlorothiazide tablets combined 50 ~ 100mg/ d of metoprolol for 8 weeks). The echocardiographic indicators including left ventricular end-systolie volume(LVESV),left ventric-ular end-diaslolic volume(LVEDV),and left ventricular ejection fraction(LVEF)were measured before and after treatment. Results Echocardiographic parameters were significantly different among 3 groups(P < 0. 05). In each group,LVESV and LVEDV significantly decreased and LVEF significantly increased after treatment(P < 0. 05). Also,LVESV and LVEDV in C group were lower than those in A group and B group,the differences were statistically significant(P < 0. 05);on the contrary, LVEF and LVEDV in C group were significantly higher than those in A group and B group(P < 0. 05). However,no such difference was noted between A group and B group(P > 0. 05). Conclusion Irbesartan and hydrochlorothiazide tablets com-bined with metoprolol is remarkably superior than irbesartan and hydrochlorothiazide tablets or metoprolol only in treating pa-tients with CHF. The combined therapy can effectively improve myocardial remodeling.
